INNOLAKE BIOPHARM
Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas.
INNOLAKE BIOPHARM
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2020-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.innolakebio.com
Total Employee:
1+
Status:
Active
Contact:
+86-21-3886 3300
Email Addresses:
[email protected]
More informations about "Innolake Biopharm"
Innolake Biopharm - Crunchbase Company Profile
Organization. Innolake Biopharm . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. ... Contact Email …See details»
INNOLAKE BIOPHARM
Innolake Biopharm is a clinical stage biotech company, dedicated to developing innovative medicines against cancer and autoimmune diseases to improve life of patients around the world.See details»
INNOLAKE BIOPHARM
Jun 5, 2023 Innolake Biopharm is a clinical stage biotech company, dedicated to developing innovative medicines against cancer and autoimmune diseases to improve life of patients …See details»
Innolake Biopharm - Company Profile & Staff Directory - ContactOut
Innolake Biopharm is a clinical stage biotech company, dedicated to developing innovative medicines against cancer and autoimmune diseases to improve the life of patients around the …See details»
Innolake Biopharm - LinkedIn
Innolake Biopharm is a clinical stage biotech company, dedicated to developing innovative medicines against cancer and autoimmune diseases to improve the life of patients around the world.See details»
Innolake Biopharm - PitchBook
Apr 7, 2021 Innolake Biopharm General Information Description. Developer of therapeutic drugs designed to overcome tumors and immune system diseases. The company is engaged with …See details»
Innolake Biopharm - Products, Competitors, Financials, Employees ...
Apr 12, 2021 innolakebio.com. Overview & Products; Financials; Founded Year 2020. Stage Series A | Alive. Total Raised $58.98M. Last Raised $13.13M | 1 yr ago. About Innolake …See details»
Innolake Biopharm - Company Profile - Tracxn
Oct 19, 2024 Innolake Biopharm - Developer of medicines against cancer and autoimmune diseases. Raised funding from 2 investors. Founded by Mingde Xia and Robert Chen in the …See details»
Innolake Biopharm (Hangzhou) Co., Ltd.: Drug pipelines, Patents ...
Aug 24, 2023 Explore Innolake Biopharm (Hangzhou) Co., Ltd. with its drug pipeline, therapeutic area, technology platform, .See details»
INNOLAKE BIOPHARM
On March 18, 2023, Innolake Biopharm, a company founded just two years ago, was granted the award of “Enterprise of Innovation Breakthrough in 2022” at the 8th Enmore Bio Conference.See details»
Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
Explore Innolake Pharmaceuticals (Hangzhou) Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 1 news, Disease Domain ...See details»
Innolake Biopharm - Contacts, Employees, Board Members
Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas.See details»
Innolake Biopharm - VentureRadar
"Innolake Biopharm is a clinical stage biotech company, dedicated to developing innovative medicines against cancer and autoimmune diseases to improve life of patients around the world.See details»
Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
了解Innolake Pharmaceuticals (Hangzhou) Co., Ltd. (英诺湖医药（杭州）有限公司)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验, 127篇新闻，疾病领域:肿瘤，免疫系统疾 …See details»
INNOLAKE BIOPHARM
Striving to build up the world’s first- and best-in-class innovative drug R&D pipeline Shanghai and Hangzhou, China, April 6, 2021 - Innolake Biopharm announced today the completion of Pre …See details»
Innolake Biopharma Scooped up ￥300 Million in Pre-Series A …
(VCBeat) Apr. 06, 2021 -- Hangzhou-based Innolake Biopharma recently completed a Pre-Series A financing of 300 million y...See details»
INNOLAKE BIOPHARM
At the opening ceremony of the “2021 Nanjing International Summit on Innovation & Investment in Medicine, Life Sciences & Healthcare Industry” on October 20, 2021, the “2021 China …See details»
项目进展 | 英诺湖医药宣布其新型A2aR选择性拮抗剂ILB-2109完成 …
近日，英诺湖医药(Innolake Biopharm)宣布其拥有全球知识产权的新型A2aR选择性拮抗剂（研发代号：ILB-2109）在治疗晚期实体瘤的I期临床试验中完成首例患者给药。该研 …See details»
INNOLAKE BIOPHARM
Shanghai, China. April 25, 2022——Innolake Biopharm today announced the first patient has been dosed in a phase 1a clinical trial of a novel A2a receptor antagonist (ILB-2109).See details»
INNOLAKE BIOPHARM
Qualifications: Master's degree or above in medicine, pharmacy or life sciences. At least 2 years of relevant experience. Knowledge/experience in pharmaceutical companies in writing …See details»